1 Buyout Bolstering Big Biotech

While Gilead (NASDAQ: GILD  ) is often thought of as king in the HIV space and is leading the race for successful interferon-free hepatitis C treatment with some astounding cure rates in clinical trials, its recent announcement that it will acquire YM BioSciences (UNKNOWN: YMI.DL2  ) highlights a lesser-known direction for the company: its oncology pipeline. In this video, Motley Fool health care analyst David Williamson discusses what the acquisition means for Gilead and its aspirations in the oncology field.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2155312, ~/Articles/ArticleHandler.aspx, 7/29/2014 1:42:43 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement